

# EpiVax

## Westin Tokyo Immunogenicity Seminar 2016



Venue: Westin Tokyo

---

### Speakers:

**Yoshimasa Takahashi, Ph.D.**

National Institute for Infectious Disease  
*Immunological memory to influenza virus*

**Roberto Carrio, Ph.D.**

Sanofi Pasteur  
*Coupling In Silico and Biological Readouts of Human Immunity Towards Engineering  
More Efficacious Pandemic and Seasonal Influenza Vaccines*

**Tomoyuki Igawa, Ph.D.**

Chugai Pharma  
*Bispecific Antibody for the Treatment of Hemophilia A and Solid Tumor*

**Hirofumi Shoda, M.D., Ph.D.**

University of Tokyo  
*Antigen-specific T cells in rheumatoid arthritis*

**Prof. Annie De Groot, MD**

Professor and Director, Institute of Immunology and Informatics,  
University of Rhode Island, CEO/CSO, EpiVax, Inc.  
*Tolerance and Immunogenicity – Can We Predict it? And Why Does it Matter?*  
*MiVax: A Computational Pipeline for Personalized Cancer Vaccine Design*

For more information visit our event page:

<http://www.epivax.com/events/westin-tokyo-immunogenicity-seminar-2016/>

# Conference Agenda

## EpiVax Westin Immunogenicity Seminar 2016 October 17<sup>th</sup>, 2016

Time	Presenter	Topic
9:40		Arrival and Coffee <i>Kaede B Meeting Room</i>
10:00		Introductions and Welcome
10:15	<b>Annie De Groot, M.D.</b> EpiVax, Inc.	<b>Keynote Talk:</b> <i>Tolerance and Immunogenicity – Can We Predict it? And Why Does it Matter?</i>
11:00	<b>Yoshimasa Takahashi, Ph.D.</b> NIID	<i>Immunological Memory to Influenza Virus</i>
11:45	<b>Roberto Carrio, Ph.D.</b> Sanofi Pasteur	<i>Coupling In Silico and Biological Readouts of Human Immunity Towards Engineering More Efficacious Pandemic and Seasonal Influenza Vaccines</i>
<b>12:30</b>	<b>Lunch (Provided)</b>	
1:30	<b>Hirofumi Shoda, M.D., Ph.D.</b> University of Tokyo	<i>Antigen-specific T cells in Rheumatoid Arthritis</i>
2:15	<b>Annie De Groot, M.D.</b> EpiVax, Inc.	<i>MiVax: A Computational Pipeline for Personalized Cancer Vaccine Design</i>
3:00	<b>Tomoyuki Igawa, Ph.D.</b> Chugai Pharmaceuticals	<i>Bispecific Antibody for the Treatment of Hemophilia A and Solid Tumor</i>
<b>3:45</b>	<b>Break</b>	
4:00	<b>Annie De Groot, M.D.</b> EpiVax, Inc.	<i>Live Demonstration of In Silico Tools</i>
4:30	<b>All Speakers</b>	Panel Discussion and Questions Topic: Relevance of Today's Talks to Protein Medicine
5:00	<b>Speakers and Attendees</b>	Cocktail Reception & Networking <i>Kiri Room</i>
<b>6:00</b>	<b>Close</b>	

For more information visit our event page:

<http://www.epivax.com/events/westin-tokyo-immunogenicity-seminar-2016/>



## **EpiVax:**

The team at **EpiVax**, Inc., led by Dr. Annie De Groot and Bill Martin, has pioneered the development of a set of immunoinformatics tools which allows researchers to predict the immunogenicity of peptides and proteins. The potential applications of this technology are vast: for instance, one could be to predict which vaccines will be most effective or which protein therapeutic drugs will have the possibility of eliciting an adverse immune response. It is a powerful research and development tool for designing effective and safe protein/peptide based therapeutics. The leaders of EpiVax, Inc. have been resolute in availing these tools to the research community. To that end, Dr. De Groot and her team, with funding from an NIH U19 grant, have developed the iVAX website where investigators can access their own set of genome sequences, proteins of interest, and tools for the analysis of vaccines and diagnostics. Using the iVAX toolkit, researchers can quickly and efficiently identify the most reactive proteins contained within a given pathogen, and optimize the antigenic content of vaccines. Furthermore, by selecting the highest quality epitopes from a protein sequence new antigens that are relevant for vaccine development can be discovered.

**For more information visit our event page:**

**<http://www.epivax.com/events/westin-tokyo-immunogenicity-seminar-2016/>**